Johnson & Johnson commits US$55B for U.S. manufacturing expansion

USA—Johnson & Johnson (J&J) has announced plans to invest over US$55 billion in U.S. manufacturing, research, and technology over the next four years, a major boost to America’s healthcare infrastructure.

This commitment represents a 25% increase from the company’s previous four-year investment cycle, highlighting J&J’s strategic shift toward domestic production—a trend that is gaining traction across numerous industries.

The initiative kicked off with the groundbreaking of a 500,000-square-foot, state-of-the-art biologics manufacturing facility in Wilson, North Carolina, valued at US$2 billion.

This advanced facility is expected to create more than 500 permanent jobs and generate a US$3 billion economic impact within its first decade.

 It will focus on the production of cancer treatments and therapies for immune-mediated and neurological disorders.

Additionally, three more manufacturing sites are planned, although their locations have not yet been revealed.

Existing J&J facilities in its Innovative Medicine and MedTech divisions will also see expansions.

J&J’s plans align with a broader trend of reshoring in the pharmaceutical industry. In February 2025, Eli Lilly announced a US$27 billion expansion across four U.S. sites, bringing its total domestic investment since 2020 to US$50 billion.

These moves reflect an increasing responsiveness from corporations to government policies aimed at boosting domestic production.

Under the Trump administration, proposed tariffs on imported drugs and an emphasis on reducing reliance on overseas manufacturing have heightened pressure on companies to strengthen their U.S. operations.

While these tariffs are intended to encourage reshoring, industry groups like the Healthcare Distribution Alliance (HDA) warn that such measures could disrupt supply chains and drive-up drug costs.

Still, the HDA supports federal investments in domestic manufacturing, highlighting improved resilience as a significant advantage. 

Moreover, foreign companies are intensifying their presence in the U.S. market, with UK-based GSK recently acquiring the U.S. biotech firm IDRx for US$1.15 billion and committing US$800 million to expand a vaccine facility in Pennsylvania.

Data from GlobalData shows a dramatic shift: outbound investments in the U.S. healthcare sector plummeted by 53% to US$3.4 billion in 2024, while inbound foreign direct investment soared by 837% to US$6.6 billion.

J&J’s US$55 billion investment is projected to contribute over US$100 billion annually to the U.S. economy, reinforcing its vital role as a driving force of domestic innovation.

The company’s emphasis on advanced therapies, robotics, and drug discovery aligns with long-term healthcare challenges, while its manufacturing expansion addresses vulnerabilities exposed by global supply chain disruptions.

Pharmaceutical leaders such as J&J and Eli Lilly are paving the way, and their investments signal the dawn of a transformative era for American industry.

As policy discussions progress, the United States is reinforcing its position as a centre for advanced healthcare production, driven by corporate strategies and government incentives.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.